Patent ID: 11911435
Assignee: GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A compound of Formula (V) or (VI):, or a pharmaceutically acceptable salt thereof, wherein
A is an antibody;
LA1, LA2 and LA3 are each independently linker moieties, with LA3 comprising 1 to 100 series-connected structure units which are selected from the group consisting of one or more glycine and alanine;
a, b and p are independently 0 or 1, that is, LA1, LA2 and LA3 are independently present or absent;
one of PCA and F is a specific recognition sequence of a ligase donor substrate and the other of PCA and F is a specific recognition sequence of the ligase acceptor substrate, wherein by the action of the ligase the PCA can bind specifically to F through an amide bond;
CCA′ is a chemical conjugation moiety;
 represents a single or double bond;
Y is a radioactive label, a fluorescent label, an affinity purification tag, a tracer molecule, an anticancer drug or a cytotoxic molecule;
z is any of the integers between 1 and 20; and
d is any of the integers between 1 and 20 wherein F is X1X2X3TX4X5, with X being leucine or asparagine, X2 being proline or alanine, X3 being any of the natural or unnatural amino acids, T being threonine, X4 representing glycine, serine or asparagine or being absent, and X5 being any of the natural or unnatural amino acid or being absent; and
wherein the PCA comprises 1 to 100 series-connected structure units which are selected from the group consisting of one or more glycine and alanine.